Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.2 USD | +13.39% | +6.80% | +86.12% |
04:39pm | Agios Says of Trial of Blood Disorder Drug Mitapivat Met Primary Endpoint; Shares Rise | MT |
02:00pm | Transcript : Agios Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.12% | 2.06B | |
+14.79% | 118B | |
+13.63% | 106B | |
-2.34% | 24.28B | |
+0.52% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-17.04% | 15.56B | |
+6.65% | 13.63B | |
+29.63% | 12.27B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints